Ovid Announces CEO Succession Plan

Rare Daily Staff

Ovid Therapeutics, which is developing therapies for rare epilepsies and seizure-related neurologic disorders, said Meg Alexander has been appointed CEO, effective Jan. 1, as Jeremy Levin will transition to executive chair of the board of directors.

The company made the announcement with its third-quarter results.

Alexander, who joined Ovid in 2021, has been instrumental in shaping the company’s pipeline and has overseen core operations and strategic initiatives, most recently in her role as president and chief operating officer.

Prior to joining Ovid, Alexander held key roles supporting the development and commercialization strategies of companies such as Pfizer, Novartis, Amgen, Janssen, Boehringer Ingelheim, Alnylam, and BioMarin, and guided global consumer brands including Nestlé and Coca-Cola. She also founded and scaled the reputation and risk management business at Syneos Health.

“Ovid is at an important inflection point. We are within months of bringing OV329 into patient trials with drug-resistant epilepsies, reading out safety data from the first-ever KCC2 direct activator, and submitting the first oral KCC2 direct activator for human studies,” Alexander said. “I’m energized to build upon this momentum, advance potentially transformative medicines for patients, and create meaningful value for shareholders.”